Citation: | et alRelationship between tumor mutational burden and efficacy of targeted therapies in patients with advanced nonsmall cell lung cancer[J]. Chin J Clin Med, 2019, 26(4): 538-542. DOI: 10.12025/j.issn.1008-6358.2019.20190157 |
[1] |
Rosenberg J E, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial[J]. Lancet, 2016,387(10031):1909-1920.
|
[2] |
Rizvi N A, Hellmann M D, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015,348(6230):124-128.
|
[3] |
Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma[J]. N Engl J Med, 2014,371(23):2189-2199.
|
[4] |
Hellmann M D, Callahan M K, Awad M M, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer[J]. Cancer Cell, 2018,33(5):853-861.
|
[5] |
Hellmann M D, Ciuleanu T E, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden[J]. N Engl J Med, 2018,378(22):2093-2104.
|
[6] |
Gandara D R, Paul S M, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J]. Nat Med, 2018,24(9):1441-1448.
|
[7] |
Forde P M, Chaft J E, Smith K N, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer[J]. N Engl J Med, 2018,378(21):1976-1986.
|
[8] |
Carbone D P, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2017,376(25):2415-2426.
|
[9] |
Carbone D P, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2017,376(25):2415-2426.
|
[10] |
Offin M, Rizvi H, Tenet M, et al. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers[J]. Clin Cancer Res, 2018. doi: 10.1158/1078-0432.
|
[11] |
Grigoriu B, Berghmans T, Meert A P. Management of EGFR mutated nonsmall cell lung carcinoma patients[J]. Eur Respir J, 2015,45(4):1132-1141.
|
[12] |
Solomon B J, Mok T, Kim D W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J]. N Engl J Med, 2014,371(23):2167-2177.
|
[13] |
Shaw A T, Kim D W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. N Engl J Med, 2013,368(25):2385-2394.
|
[14] |
Shaw A T, Ou S H, Bang Y J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014,371(21):1963-1971.
|
[15] |
Reungwetwattana T, Ou S H. MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval[J]. Transl Lung Cancer Res, 2015,4(6):820-824.
|